Alivus Life Sciences (BOM:543322) Change In Receivables : ₹0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alivus Life Sciences Change In Receivables?

Alivus Life Sciences's change in receivables for the quarter that ended in Dec. 2024 was ₹0 Mil. It means Alivus Life Sciences's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Alivus Life Sciences's change in receivables for the fiscal year that ended in Mar. 2024 was ₹-173 Mil. It means Alivus Life Sciences's Accounts Receivable increased by ₹173 Mil from Mar. 2023 to Mar. 2024 .

Alivus Life Sciences's Accounts Receivable for the quarter that ended in Dec. 2024 was ₹0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Alivus Life Sciences's Days Sales Outstanding for the three months ended in Dec. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Alivus Life Sciences's liquidation value for the three months ended in Dec. 2024 was ₹0 Mil.

Alivus Life Sciences Change In Receivables Historical Data

The historical data trend for Alivus Life Sciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alivus Life Sciences Change In Receivables Chart

Alivus Life Sciences Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Receivables

Get a 7-Day Free Trial

-1,976.33

-410.20

289.14

-2,072.12

-173.33

Alivus Life Sciences Quarterly Data
	Mar19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Alivus Life Sciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Alivus Life Sciences (BOM:543322) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Alivus Life Sciences's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	6418.44	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Alivus Life Sciences's accounts receivable are only considered to be worth 75% of book value:

Alivus Life Sciences's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0	-	0	+	0.75 * 0	+	0.5 * 0
=	0

Alivus Life Sciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Alivus Life Sciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Alivus Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alivus Life Sciences Ltd (BOM:543322) » Definitions » Change In Receivables

Traded in Other Exchanges

ALIVUS:India

Address

470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099

Website

https://www.alivus.com

Alivus Life Sciences Ltd, formerly Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Alivus Life Sciences Headlines

No Headlines